{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:16:07Z","timestamp":1786976167680,"version":"build-2736575974"},"reference-count":79,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","award":["R21HS029399e"],"award-info":[{"award-number":["R21HS029399e"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["P30AR070549"],"award-info":[{"award-number":["P30AR070549"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["P30AR076316"],"award-info":[{"award-number":["P30AR076316"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["ACR Open Rheumatology"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We evaluated the efficacy and safety profiles of JAK inhibitors (JAKi) and biologic disease\u2010modifying antirheumatic drugs (bDMARDs) when used with or without methotrexate (MTX) for the treatment of nonsystemic forms of juvenile idiopathic arthritis (nsJIA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Randomized clinical trials (RCTs) investigating efficacy and safety outcomes of JAKi or bDMARDs for the nsJIA population up to 2023 were searched in\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/ClinicalTrial.gov\">ClinicalTrial.gov<\/jats:ext-link>\n                      , PubMed, EMBASE, and Cochrane databases. Bayesian arm\u2010based network meta\u2010analysis compared efficacy as measured by Juvenile Idiopathic Arthritis\u2010American College of Rheumatology 70 (JIA\u2010ACR70) improvement and safety based on rates of serious adverse events (SAEs) among all therapies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eligible studies included 45 citations from 16 RCTs (7 parallel and 9 withdrawal trials) with a total of 1,821 participants that investigated nine bDMARDs, three with and six without MTX co\u2010treatment, and two JAKis (tofacitinib and baricitnib). The reported SAE incidence rates ranged from 0 to 0.3 per person\u2010year of follow\u2010up; none of the pairwise comparisons were statistically significant. The JIA\u2010ACR70 improvement by 16 weeks of treatment ranged from 11.3% to 89.5%. Compared with controls, significant JIA\u2010ACR70 improvements were observed for etanercept, golimumab, and all three combination therapies (adalimumab+MTX, etanercept+MTX, and infliximab+MTX), with odds ratios ranging from 2.97 to 3.99. No significant pairwise comparisons between bDMARDs and JAKi versus bDMARDs were noted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Overall, no significant evidence was found for efficacy and safety profiles in pairwise comparisons of JAKis and bDMARDs. Future studies will expand the meta\u2010analysis by including non\u2010RCT studies and individual participant data.\n                      <jats:boxed-text content-type=\"graphic\" position=\"anchor\">\n                        <jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" mimetype=\"image\/png\" position=\"anchor\" specific-use=\"enlarged-web-image\" xlink:href=\"graphic\/acr211788-toc-0001-m.png\">\n                          <jats:alt-text>image<\/jats:alt-text>\n                        <\/jats:graphic>\n                      <\/jats:boxed-text>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/acr2.11788","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T14:23:37Z","timestamp":1739888617000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparative Effectiveness and Safety of the\n                    <scp>JAK<\/scp>\n                    Inhibitors and Biologic Disease\u2010Modifying Antirheumatic Drugs in Treating Children With Nonsystemic Juvenile Idiopathic Arthritis: A Bayesian Meta\u2010Analysis of Randomized Controlled Trials"],"prefix":"10.1002","volume":"7","author":[{"given":"Yuxiang","family":"Li","sequence":"first","affiliation":[{"name":"Cincinnati Children's Hospital Medical Center  Cincinnati Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9724-675X","authenticated-orcid":false,"given":"Bin","family":"Huang","sequence":"additional","affiliation":[{"name":"Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine  Cincinnati Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3093-2568","authenticated-orcid":false,"given":"Sandra","family":"Andorf","sequence":"additional","affiliation":[{"name":"Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine  Cincinnati Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomeng","family":"Yue","sequence":"additional","affiliation":[{"name":"James L. Winkle College of Pharmacy, University of Cincinnati  Cincinnati Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1604-0130","authenticated-orcid":false,"given":"Daniel J.","family":"Lovell","sequence":"additional","affiliation":[{"name":"Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine  Cincinnati Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9478-2987","authenticated-orcid":false,"given":"Hermine I.","family":"Brunner","sequence":"additional","affiliation":[{"name":"Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine  Cincinnati Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23087"},{"issue":"1","key":"e_1_2_6_3_1","first-page":"146","article-title":"Biologics in juvenile idiopathic arthritis\u2010main advantages and major challenges: a narrative review","volume":"36","author":"Adrovic A","year":"2020","journal-title":"Arch Rheumatol"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00921-2"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01255-1"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12144695"},{"key":"e_1_2_6_7_1","volume-title":"Olumiant \u2010 baricitinib tablet, film coated. Prescribing information","year":"2022"},{"issue":"2","key":"e_1_2_6_8_1","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty RE","year":"2004","journal-title":"J Rheumatol"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-023-00798-8"},{"key":"e_1_2_6_11_1","volume-title":"What is a serious adverse event?","year":"2023"},{"key":"e_1_2_6_12_1","volume-title":"Results data element definitions for interventional and observational studies","year":"2024"},{"key":"e_1_2_6_13_1","volume-title":"Doing Bayesian Data Analysis: A Tutorial with R, JAGS, and Stan","author":"Kruschke J.","year":"2014"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-022-01657-y"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.7156"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1153"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/1740774513498322"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.8360"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3767"},{"key":"e_1_2_6_20_1","unstructured":"A study of the efficacy and safety of adalimumab in pediatric subjects with enthesitis related arthritis. ClinicalTrials.gov identifier: NCT01166282. Updated July 12 2021. Accessed Feburary 23 2024.https:\/\/clinicaltrials.gov\/show\/NCT01166282"},{"key":"e_1_2_6_21_1","unstructured":"BMS\u2010188667 in children and adolescents with juvenile rheumatoid arthritis. ClinicalTrials.gov identifier: NCT00095173. Updated January 18 2017. Accessed Feburary 23 2024.https:\/\/clinicaltrials.gov\/show\/NCT00095173"},{"issue":"3","key":"e_1_2_6_22_1","first-page":"A740.2","article-title":"Efficacy of biologic treatments in juvenile idiopathic arthritis with a polyarticular course: an indirect comparison","volume":"72","author":"Sawyer L","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-eular.6177"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201991"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.5414\/CP203791"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.07.001"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev382"},{"issue":"3","key":"e_1_2_6_28_1","first-page":"260","article-title":"THU0308 Indirect comparison of ACR response of biologic treatments in active SJIA","volume":"71","author":"Diamantopoulos A","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1201\/b16018"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12030353"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60250-0"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1608345"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31618-5"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.37711"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12134527"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001091"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/biom.13716"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.5844"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22657"},{"key":"e_1_2_6_41_1","unstructured":"A study of the efficacy and safety of adalimumab in pediatric subjects with enthesitis related arthritis. Trialsearch.who.int identifier: EUCTR2009\u2010017938\u201046\u2010Outside\u2010EU\/EEA. Updated July 10 2015. Accessed Feburary 23 2024.https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2009-017938-46-Outside-EU\/EEA"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-020-00488-9"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-10-59"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-017-0138-4"},{"key":"e_1_2_6_45_1","unstructured":"BeSt for kids: comparing treatment strategies in juvenile idiopathic arthritis. Trialsearch.who.int identifier: NL\u2010OMON26585. December 3 2008. Updated February 28 2024. Accessed Feburary 23 2024.https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=NL-OMON26585"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213902"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.34343"},{"key":"e_1_2_6_48_1","unstructured":"Trial of early aggressive drug therapy in juvenile idiopathic arthritis. Clinicaltrials.gov identifier: NCT00443430. Updated May 31 2013. Accessed Feburary 23 2024.https:\/\/clinicaltrials.gov\/show\/NCT00443430"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25003"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.131503"},{"key":"e_1_2_6_51_1","unstructured":"Etanercept plus methotrexate versus methotrexate alone in children with polyarticular course juvenile rheumatoid arthritis. Clinicaltrials.gov identifier: NCT03781375. Updated August 2 2019. Accessed Feburary 23 2024.https:\/\/clinicaltrials.gov\/show\/NCT03781375"},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.100354"},{"key":"e_1_2_6_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22838"},{"key":"e_1_2_6_54_1","unstructured":"A study of the safety and effectiveness of infliximab (remicade) in patients with juvenile rheumatoid arthritis. Clinicaltrials.gov identifier: NCT00036374. Updated May 17 2011. Accessed Feburary 23 2024.https:\/\/clinicaltrials.gov\/show\/NCT00036374"},{"key":"e_1_2_6_55_1","doi-asserted-by":"publisher","DOI":"10.1186\/1546-0096-8-24"},{"key":"e_1_2_6_56_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.143347"},{"key":"e_1_2_6_57_1","unstructured":"Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis. ClinicalTrials.gov identifier: NCT01015547. Updated October 15 2015. Accessed Feburary 23 2024.https:\/\/clinicaltrials.gov\/show\/NCT01015547"},{"key":"e_1_2_6_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60998-8"},{"key":"e_1_2_6_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27431"},{"key":"e_1_2_6_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2018.05.042"},{"key":"e_1_2_6_61_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706290"},{"key":"e_1_2_6_62_1","unstructured":"Study of human anti\u2010TNF monoclonal antibody adalimumab in children with polyarticular juvenile idiopathic arthritis (JIA). ClinicalTrials.gov identifier: NCT00048542. Updated August 22 2011. Accessed Feburary 23 2024.https:\/\/clinicaltrials.gov\/show\/NCT00048542"},{"key":"e_1_2_6_63_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001208"},{"key":"e_1_2_6_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.10710"},{"key":"e_1_2_6_65_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200003163421103"},{"key":"e_1_2_6_66_1","unstructured":"Remission induction by etanercept in enthesitis related arthritis JIA\u2010patients (juvenile undifferentiated spondylarthropathy). Trialsearch.who.int identifier: EUCTR2010\u2010020423\u201051\u2010DE. February 17 2011. Updated December 7 2015. Accessed Feburary 23 2024.https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2010-020423-51-DE"},{"key":"e_1_2_6_67_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39145"},{"key":"e_1_2_6_68_1","unstructured":"A study of the safety and efficacy of CNTO 148 (golimumab) in children with juvenile idiopathic arthritis (JIA) and multiple joint involvement who have poor response to methotrexate (GO KIDS). ClinicalTrials.gov identifier: NCT01230827. Updated April 4 2016. Accessed Feburary 23 2024.https:\/\/clinicaltrials.gov\/show\/NCT01230827"},{"key":"e_1_2_6_69_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210456"},{"key":"e_1_2_6_70_1","unstructured":"Secukinumab safety and efficacy in juvenile psoriatic arthritis (JPsA) and enthesitis\u2010related arthritis (ERA). Trialsearch.who.int identifier: NCT03031782. November 2 2016. Updated August 22 2022. Accessed Feburary 23 2024.https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=NCT03031782"},{"key":"e_1_2_6_71_1","unstructured":"Secukinumab safety and efficacy in juvenile psoriatic arthritis (JPsA) and enthesitis\u2010related arthritis (ERA). Clinicaltrials.gov identifier: NCT03031782. Updated August 15 2022. Accessed Feburary 23 2024.https:\/\/clinicaltrials.gov\/study\/NCT03031782"},{"key":"e_1_2_6_72_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222849"},{"key":"e_1_2_6_73_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4071-9"},{"key":"e_1_2_6_74_1","unstructured":"A study of tocilizumab in patients with active polyarticular juvenile idiopathic arthritis. ClinicalTrials.gov identifier: NCT00988221. Updated July 26 2017. Accessed Feburary 23 2024.https:\/\/clinicaltrials.gov\/show\/NCT00988221"},{"key":"e_1_2_6_75_1","unstructured":"A 24 week randomized double\u2010blind placebo controlled withdrawal trial with a 16 week open label lead\u2010in phase and 64 week open label follow\u2010up to evaluate the efficacy and safety of tocilizumab in patients with active polyarticular\u2010course juvenile idiopathic arthritis. Trialsearch.who.int identifer: EUCTR2009\u2010011593\u201015\u2010GB. July 6 2009. Updated November 25 2019. Accessed Feburary 23 2024.https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2009-011593-15-GB"},{"key":"e_1_2_6_76_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41528"},{"key":"e_1_2_6_77_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205351"},{"key":"e_1_2_6_78_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170326"},{"key":"e_1_2_6_79_1","unstructured":"Efficacy study of tofacitinib in pediatric JIA population. ClinicalTrials.gov identifier: NCT02592434. Updated April 13 2020.https:\/\/clinicaltrials.gov\/show\/NCT02592434"},{"key":"e_1_2_6_80_1","unstructured":"A study of baricitinib compared to placebo in children with juvenile idiopathic arthritis (JIA). Trialsearch.who.int identifier: NCT03773978. December 11 2018. Updated February 21 2022.https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=NCT03773978"}],"container-title":["ACR Open Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr2.11788","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T14:30:31Z","timestamp":1759415431000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr2.11788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":79,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1002\/acr2.11788"],"URL":"https:\/\/doi.org\/10.1002\/acr2.11788","archive":["Portico"],"relation":{},"ISSN":["2578-5745","2578-5745"],"issn-type":[{"value":"2578-5745","type":"print"},{"value":"2578-5745","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"2024-06-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e11788"}}